US National OCS Liver Perfusion (OLP) Registry
Launched by TRANSMEDICS · Jul 10, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The US National OCS Liver Perfusion (OLP) Registry is a study that aims to gather important information about liver transplant patients. It focuses on understanding how a special technique called OCS (Organ Care System) liver perfusion affects transplant outcomes compared to other methods used to preserve donated livers. This study is being conducted at multiple hospitals and is overseen by independent experts to ensure the information collected is reliable.
If you or a family member has received a liver transplant, you may be eligible to participate in this registry. The study is open to all liver transplant recipients, regardless of age or gender. Participants can expect to have their transplant journey monitored and documented, which will help improve future liver transplant procedures. This research is crucial as it aims to enhance the overall success of liver transplants and care for patients like you.
Gender
ALL
Eligibility criteria
- • All liver transplant recipients.
About Transmedics
TransMedics is a pioneering medical technology company focused on transforming the organ transplant process through innovative solutions. With a commitment to improving patient outcomes, TransMedics has developed advanced organ preservation and transportation systems, notably the Organ Care System (OCS), which enables the preservation and assessment of donor organs in a more physiologically relevant environment. By leveraging cutting-edge technology, TransMedics aims to enhance the viability of organs for transplantation, ultimately expanding the donor pool and improving the lives of patients awaiting transplants. The company’s dedication to research and clinical trials underscores its mission to advance the field of transplantation and contribute to better healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Philadelphia, Pennsylvania, United States
Omaha, Nebraska, United States
San Francisco, California, United States
Lexington, Kentucky, United States
Durham, North Carolina, United States
Dallas, Texas, United States
Ann Arbor, Michigan, United States
Atlanta, Georgia, United States
Burlington, Massachusetts, United States
La Jolla, California, United States
Salt Lake City, Utah, United States
Phoenix, Arizona, United States
Houston, Texas, United States
Jacksonville, Florida, United States
Saint Louis, Missouri, United States
Charlotte, North Carolina, United States
New York, New York, United States
San Antonio, Texas, United States
Rochester, Minnesota, United States
Patients applied
Trial Officials
Ahmed Elbetanony, MD
Study Director
TransMedics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported